Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis
Autor: | Alan F. Hofmann, Mary Erickson, Kristoffer Kjærgaard, Susanne Keiding, David Shapiro, Michael Sørensen, Anna C. Schacht, Ole Lajord Munk, Jacob Horsager, Kim Frisch |
---|---|
Rok vydání: | 2021 |
Předmět: |
0301 basic medicine
INDOCYANINE GREEN Receptors Cytoplasmic and Nuclear Chronic liver disease Gastroenterology chemistry.chemical_compound 0302 clinical medicine CIRRHOSIS GENE-EXPRESSION Bile acid Liver Cirrhosis Biliary Ursodeoxycholic Acid Intrahepatic cholestasis Obeticholic acid Middle Aged G protein-coupled bile acid receptor Ursodeoxycholic acid Treatment Outcome FXR HEPATOBILIARY SECRETION CHOLYLSARCOSINE Alkaline phosphatase Female 030211 gastroenterology & hepatology FARNESOID-X-RECEPTOR medicine.drug medicine.medical_specialty medicine.drug_class Bile acid-binding proteins Molecular imaging Chenodeoxycholic Acid digestive system Bile Acids and Salts Excretion 03 medical and health sciences Farnesoid X receptor Double-Blind Method Gastrointestinal Agents Internal medicine medicine Humans KINETICS Aged Hepatology business.industry Biological Transport Alkaline Phosphatase medicine.disease URSODEOXYCHOLIC ACID SALT EXPORT PUMP Bile Ducts Intrahepatic 030104 developmental biology chemistry Positron-Emission Tomography Liver cirrhosis Hepatocytes business |
Zdroj: | Kjærgaard, K, Frisch, K, Sørensen, M, Munk, O L, Hofmann, A F, Horsager, J, Schacht, A C, Erickson, M, Shapiro, D A & Keiding, S 2021, ' Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis ', Journal of Hepatology, vol. 74, no. 1, pp. 58-65 . https://doi.org/10.1016/j.jhep.2020.07.028 |
ISSN: | 0168-8278 |
Popis: | Background & Aims: Obeticholic acid (OCA) is an agonist of the nuclear bile acid receptor farnesoid X receptor, which regulates hepatic bile acid metabolism. We tested whether OCA treatment would influence hepatic transport of conjugated bile acids in patients with primary biliary cholangitis (PBC) who responded inadequately to treatment with ursodeoxycholic acid (UDCA). Methods: Eight UDCA-treated patients with PBC with alkaline phosphatase ≥1.5 times the upper limit of normal range participated in a double-blind, placebo-controlled study. While continuing on UDCA, the patients were randomised to two 3-month crossover treatment periods with placebo and OCA, in random order, separated by a 1-month washout period without study treatment. After each of the two treatment periods, we determined rate constants for transport of conjugated bile acids between blood, hepatocytes, biliary canaliculi, and bile ducts by positron emission tomography of the liver using the conjugated bile acid tracer [N-methyl- 11C]cholylsarcosine ( 11C-CSar). The hepatic blood perfusion was measured using infusion of indocyanine green and Fick's principle. Results: Compared with placebo, OCA increased hepatic blood perfusion by a median of 11% (p = 0.045), the unidirectional uptake clearance of 11C-CSar from blood into hepatocytes by a median of 11% (p = 0.01), and the rate constant for secretion of 11C-CSar from hepatocytes into biliary canaliculi by a median of 73% (p = 0.03). This resulted in an OCA-induced decrease in the hepatocyte residence time of 11C-CSar by a median of 30% (p = 0.01), from group median 11 min to 8 min. Conclusions: This study of UDCA-treated patients with PBC showed that, compared with placebo, OCA increased the hepatic transport of the conjugated bile acid tracer 11C-CSar, and thus endogenous conjugated bile acids, from hepatocytes into biliary canaliculi. As a result, OCA reduced the time hepatocytes are exposed to potentially cytotoxic bile acids. Lay summary: Primary biliary cholangitis is a chronic liver disease in which the small bile ducts are progressively destroyed. We tested whether the treatment with obeticholic acid (OCA) would improve liver excretion of bile acids compared with placebo in 8 patients with primary biliary cholangitis. A special scanning technique (PET scan) showed that OCA increased the transport of bile acids from blood to bile. OCA thereby reduced the time that potentially toxic bile acids reside in the liver by approximately one-third. |
Databáze: | OpenAIRE |
Externí odkaz: |